

François Guérard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296255/publications.pdf>

Version: 2024-02-01

28
papers

856
citations

430874

18
h-index

610901

24
g-index

30
all docs

30
docs citations

30
times ranked

1142
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigation of Zr(^{IV}) and ⁸⁹ Zr(^{IV}) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. <i>Chemical Communications</i> , 2013, 49, 1002-1004.	4.1	99
2	Production of [²¹¹ At]-Astatinated Radiopharmaceuticals and Applications in Targeted α -Particle Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 1-20.	1.0	94
3	Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The ‘‘Hopeful Eight’’. <i>Pharmaceutics</i> , 2021, 13, 906.	4.5	69
4	Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO ‘‘a selected review. <i>Nuclear Medicine Review</i> , 2011, 14, 90-95.	0.5	67
5	Rational Design, Synthesis, and Evaluation of Tetrahydroxamic Acid Chelators for Stable Complexation of Zirconium(IV). <i>Chemistry - A European Journal</i> , 2014, 20, 5584-5591.	3.3	63
6	Cell Tracking in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2020, 7, 34.	2.6	52
7	Tumor Immunotargeting Using Innovative Radionuclides. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3932-3954.	4.1	51
8	Immuno-PET for Clinical Theranostic Approaches. <i>International Journal of Molecular Sciences</i> , 2017, 18, 57.	4.1	50
9	Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts. <i>Chemistry - A European Journal</i> , 2016, 22, 12332-12339.	3.3	33
10	Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146.	4.6	31
11	Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals. <i>Accounts of Chemical Research</i> , 2021, 54, 3264-3275.	15.6	30
12	Radioimmunoconjugates for treating cancer: recent advances and current opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 813-819.	3.1	27
13	Investigation of the complexation of ^{nat} Zr(^{IV}) and ⁸⁹ Zr(^{IV}) by hydroxypyridinones for the development of chelators for PET imaging applications. <i>Dalton Transactions</i> , 2017, 46, 4749-4758.	3.3	26
14	Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 167-174.	3.0	25
15	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 445.	4.1	23
16	Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5975-5980.	3.0	22
17	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between ⁸⁹ Zr- and ⁶⁴ Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2564.	4.1	22
18	Feasibility of the radioastatination of a monoclonal antibody with astatine- ²¹¹ purified by wet extraction. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 379-383.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies. <i>Chemical Science</i> , 2021, 12, 1458-1468.	7.4	18
20	Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. <i>Cancers</i> , 2020, 12, 2721.	3.7	11
21	Radioiodinated and astatinated NHC rhodium complexes: Synthesis. <i>Nuclear Medicine and Biology</i> , 2014, 41, e23-e29.	0.6	10
22	211 At and 125 I Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again. <i>Chemistry - A European Journal</i> , 2021, , .	3.3	5
23	Radioimmunotherapy of Lymphomas. , 2019, , 113-121.		3
24	Reply to the "Comment on "Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging" by A. Bianchi and M. Savastano, <i>Chem. Commun.</i> , 2020, 56, DOCC01189D. <i>Chemical Communications</i> , 2020, 56, 12667-12668.	4.1	2
25	Prospects for Enhancing Efficacy of Radioimmunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 139-153.	0.1	1
26	Radiolabeling chemistry with heavy halogens iodine and astatine. , 2022, , 121-132.		1
27	Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts. <i>Chemistry - A European Journal</i> , 2016, 22, 12205-12205.	3.3	0
28	How radiolysis impacts astatine speciation?. <i>Radiation Physics and Chemistry</i> , 2022, 198, 110224.	2.8	0